TRHC earnings

Continued Strong Organic Revenue Growth of 24% Second Quarter Adjusted EBITDA of $6.3 Million Increased More Than 3x Compared to Second Quarter 2022 MOORESTOWN, N.J., Aug. 7, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC) ("TRHC" or the "Company"), a leading healthcare company advancing personalized, comprehensive care for value-based care organizations, today reported financial results for the second quarter ended June 30, 2023. Highlights from the second quarter ended June 30, 2023 include: Second quarter revenue from continuing operations of $90.0 million

MOORESTOWN, N.J., July 25, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), will hold a conference call and webcast to discuss its second quarter 2023 financial results Tuesday, August 8, 2023 at 8:30 a.m. EDT. The Company's financial results for the second quarter 2023 ended June 30, 2023, will be released after the close of the market Monday, August 7, 2023. Those interested in participating via webcast in listen-only mode can access the event here. For participants who would like to participate via telephone, please register here to receive the dial-in numbe

First Quarter Results Show Benefits of Consistent Execution on Financial and Strategic Objectives First Quarter Revenue Growth of 32% Compared to First Quarter 2022 Raises Full Year 2023 Revenue and Adjusted EBITDA Guidance MOORESTOWN, N.J., May 8, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC) ("TRHC" or the "Company"), a leading healthcare technology company advancing the safe use of medications, today reported financial results for the first quarter ended March 31, 2023. Highlights from the first quarter ended March 31, 2023, include: First quarter revenu

MOORESTOWN, N.J., April 26, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), will hold a conference call and webcast to discuss its first quarter 2023 financial results Tuesday, May 9, 2023 at 8:30 a.m. EDT. The Company's financial results for the first quarter 2023 ended March 31, 2023, will be released after the close of the market Monday, May 8, 2023. Those interested in participating via webcast in listen-only mode can access the event here. For participants who would like to participate via telephone, please register here to receive the dial-in number alon

Fourth Quarter Concludes Successful Transformational Year, With Company Sharpening Focus and Laying a Foundation for Sustainable, Profitable Growth Recently Completed Sales of SinfoníaRx and DoseMe Shares Full Year 2023 Revenue Guidance and Adjusted EBITDA Guidance MOORESTOWN, N.J., March 6, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC) ("TRHC" or the "Company"), a leading healthcare technology company advancing the safe use of medications, today reported financial results for the fourth quarter and full year ended December 31, 2022. Highlights from fourth

MOORESTOWN, N.J., March 2, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC), a leading healthcare technology company advancing the safe use of medications, today announced that it completed the sale of its SinfoníaRx business to Cureatr, following the sale of its DoseMeRx business to an affiliate of Fairlong Capital LLC earlier this year. The combined proceeds are $11 million. "The successful sale of these two businesses, along with the sale of PrescribeWellness in August 2022, completes the strategic divestitures that we announced last year, advancing our comm

MOORESTOWN, N.J., Feb. 21, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), will hold a conference call and webcast to discuss its fourth quarter and full year 2022 financial results Tuesday, March 7, 2023 at 8:30 a.m. EDT. The Company's financial results for the fourth quarter and full year ended December 31, 2022, will be released after the close of the market Monday, March 6, 2023. Those interested in participating via webcast in listen-only mode can access the event here. For participants who would like to participate via telephone, please register here to

Revenue from continuing operations of $77.1 million increased 14% vs. a year agoGAAP net loss from continuing operations of $25.9 million vs. $11.8 million a year agoAdjusted EBITDA from continuing operations of $2.1 million vs. $3.1 million a year agoCash of $80.8 million as of September 30, 2022, vs. $26.5 million as of June 30, 2022MOORESTOWN, N.J., Nov. 3, 2022 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC), a leading healthcare technology company advancing the safe use of medications, today reported financial results for the third quarter ended September 30, 2022.

MOORESTOWN, N.J., Oct. 20, 2022 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC), will hold a conference call and webcast to discuss its third quarter 2022 operating results Friday, November 4, 2022 at 8:30 a.m. EDT. The Company's financial results for the third quarter ended September 30, 2022, will be released after the close of the market Thursday, November 3, 2022. Those interested in participating via webcast in listen-only mode can access the event here. For participants who would like to participate via telephone, please register here to receive the dial-in n

MOORESTOWN, N.J., July 25, 2022 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC), will hold a conference call and webcast to discuss its second quarter 2022 operating results Friday, August 5, 2022 at 8:30 a.m. EDT. The Company's financial results for the second quarter ended June 30, 2022, will be released after the close of the market Thursday, August 4, 2022. Those interested in participating via webcast in listen-only mode can access the event here . For participants who would like to participate via telephone, please register here to receive the dial-in number

First quarter 2022 revenue of $67.1 million from continuing operations includes CareVention HealthCare revenue of $66.3 million, up 19% vs. a year agoPlanned sales of PrescribeWellness, SinfoníaRx, and DoseMe expected to add significant liquidity, reduce net debt, and provide financial flexibilityGAAP net loss from continuing operations of $20.4 millionAdjusted EBITDA of $2.5 millionMOORESTOWN, N.J., May 5, 2022 /PRNewswire/ -- Tabula Rasa HealthCare, Inc. ("TRHC", the "Company," "we," "us," or "our") (NASDAQ:TRHC), a leading healthcare technology company advancing the safe use of medications, today reported financial results for the first quarter ended March 31, 2022.

MOORESTOWN, N.J., April 21, 2022 /PRNewswire/ -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), will hold a conference call and webcast to discuss its first quarter 2022 operating results Friday, May 6, 2022 at 8:30 a.m. EDT. The conference call will be hosted by TRHC CEO, Chairman and Founder, Calvin H. Knowlton, Ph.D.; TRHC Co-Founder and President, Orsula V. Knowlton, PharmD, MBA; TRHC President, Brian W. Adams; and TRHC Chief Financial Officer, Thomas Cancro. The Company's financial results for the first quarter ended March 31, 2022, will be released after the close of the market Thursday, May 5, 2022.

MOORESTOWN, N.J., Feb. 24, 2022 /PRNewswire/ -- Tabula Rasa HealthCare, Inc. ("TRHC") (NASDAQ:TRHC), a leading healthcare technology company advancing the safe use of medications, today reported financial results for the fourth quarter and full year ended December 31, 2021. "Our fourth quarter results represent solid execution with double-digit growth across three of our four major revenue streams. We have made material progress on the three strategic objectives we outlined in our third quarter earnings report, specifically, leadership changes, the further consideration of the

MOORESTOWN, N.J., Feb. 10, 2022 /PRNewswire/ -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), will hold a conference call and webcast to discuss its fourth quarter and full year 2021 operating results Friday, February 25, 2022 at 8:30 a.m. EDT. The conference call will be hosted by TRHC CEO, Chairman and Founder, Calvin H. Knowlton, Ph.D.; TRHC Co-Founder and President, Orsula V. Knowlton, PharmD, MBA; and TRHC Co-President and Chief Financial Officer, Brian W. Adams. The Company's financial results for the fourth quarter and full year 2021 ending December 31, 2021, will be released after the close of the market Thursday, February 24, 2021.

MOORESTOWN, N.J., Nov. 4, 2021 /PRNewswire/ -- Tabula Rasa HealthCare, Inc. ("TRHC") (NASDAQ:TRHC), a leading healthcare technology company advancing the safe use of medications, today reported financial results for the third quarter ended September 30, 2021. "Our improved third quarter revenue growth was driven by continued strength in PACE and our CareVention HealthCare segment. While I am pleased with our markedly improved organic growth, we are not satisfied with these results and are taking a number of important steps to better position the company to deliver higher growt

MOORESTOWN, N.J., Oct. 21, 2021 /PRNewswire/ -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), will hold a conference call and webcast to discuss its third quarter 2021 operating results  Friday, November 5, 2021 at 8:30 a.m. EDT. The conference call will be hosted by TRHC CEO, Chairman and Founder, Calvin H. Knowlton, Ph.D.; TRHC Co-Founder and President, Orsula V. Knowlton, PharmD, MBA; and TRHC Chief Financial Officer, Brian W. Adams. The Company's financial results for the third quarter 2021 ending September 30, 2021, will be released after the close of the market Thursday, November 4, 2021.

MOORESTOWN, N.J., Sept. 27, 2021 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (TRHC) (NASDAQ:TRHC), a leading healthcare technology company advancing the safe use of medications, today announced it will host a conference call and webcast to discuss its recently published, peer-reviewed three-part series, Innovative Enhanced Medication Therapy Management Model: Medication Risk Score, Medication Safety Review, and Health Care Outcomes, in the September issue of The American Journal of Managed Care. The conference call will be hosted by TRHC CEO, Chairman and Founder, Calvin H.

MOORESTOWN, N.J., Aug. 5, 2021 /PRNewswire/ -- Tabula Rasa HealthCare, Inc. ("TRHC") (NASDAQ:TRHC), a leading healthcare technology company advancing the safe use of medications, today reported financial results for the second quarter ended June 30, 2021. "The continued strong recovery in PACE and our CareVention HealthCare segment led our second quarter revenue and profitability to be at the high end of our guidance range. As we look ahead to the second half of 2021, we expect our organic revenue growth rates to increase significantly as compared with the first half of 2021.